16 July 2021: Original Paper
Risk Factors Influencing the Outcomes of Kidney Re-Transplantation
Anke Schwarz 1ADEF** , Frank Schäfer 1AB* , Theodor Framke 2CD , Silvia Linnenweber-Held 1AB , Nicolas Richter 3BD , Hermann Haller 1DEDOI: 10.12659/AOT.928922
Ann Transplant 2021; 26:e928922
Table 1 Demographic data of group TX1 (first transplantation) and TX2 (re-transplantation).
| TX1 | TX2 | p-value | |
|---|---|---|---|
| Recipient age (yrs) | 47.2±12.6 | 46.6±13.0 | 0.0640 |
| Recipient age | |||
| ≤50 yrs | 100 (61.7%) | 100 (61.7%) | 1 |
| Donor age (yrs) | 48.9±14.4 | 48.1±15.3 | 0.5491 |
| Donor age | 0.7357 | ||
| ≤50 yrs | 80 (49.4%) | 77 (47.5%) | |
| Gender Female | 56 (34.6%) | 56 (34.6%) | NA |
| Duration of dialysis (mos) | 65.6±33.9 | 113.0±52.5 | |
| Duration of dialysis | |||
| ≤60 Months | 68 (42.0%) | 22 (13.6%) | |
| >60 Months | 94 (58.0%) | 140 (86.4%) | |
| Kind of donation (living) | 17 (10.5%) | 17 (10.5%) | NA |
| Panel reactive antibodies >30% | 3 (1.9%) | 25 (15.4%) | |
| HLA mismatches | 2.08±1.65 | 2.54±1.75 | 0.0129 |
| HLA Mismatches | |||
| 0–3 | 134 (82.7%) | 118 (72.8%) | 0.0209 |
| 4–6 | 28 (17.3%) | 44 (27.2%) | |
| Cold ischemia time (min) | 875.9±428.7 | 940.6±429.1 | 0.0518 |
| Cold ischemia time (min) | |||
| 47 (29.0%) | 37 (22.8%) | 0.0956 | |
| >700 | 115 (71.0%) | 125 (77.2%) | |
| Patients with delayed graft function | 41 (25.3%) | 43 (26.5%) | 0.7928 |
| S-creatinine at hospital dismissal (μmol/L) | 189.0±121.8 | 186.2±116.2 | 0.8373 |
| S-creatinine at Hospital Dismissal (μmol/L) | |||
| 71 (43.8%) | 76 (46.9%) | 0.5413 | |
| ≥150 | 91 (56.2%) | 86 (53.1%) | |
| Hospital stay at transplantation (days) | 21.6±12.1 | 25.1±12.9 | 0.0135 |
| Patients with rejection episode | 59 (36.4%) | 60 (37.0%) | 0.9081 |
| Mean number of rejections | 0.56±0.87 | 0.56±0.92 | 1 |
| Patients with humoral rejection (humoral or mixed) | 17 (10.5%) | 20 (12.4%) | 0.6121 |
| Patients with CMV infection (clinical) | 23 (14.2%) | 17 (10.5%) | 0.3173 |
| Patients with BK virus nephropathy | 9 (5.6%) | 6 (3.7%) | 0.4054 |
| Number of comorbidities | 2.23±1.09 | 2.41±1.16 | 0.1449 |
| Patients with comorbidities | |||
| 0–2 | 99 (61.1%) | 85 (52.5%) | 0.0754 |
| 3–5 | 63 (38.9%) | 77 (47.5%) | |
| Cardiovasccular disease | 65 (40.1%) | 61 (37.7%) | 0.5930 |
| Diabetes | 16 (9.9%) | 9 (5.6%) | 0.1266 |
| Hyperlipoproteinemia | 59 (36.4%) | 71 (43.8%) | 0.1742 |
| Lung disease | 12 (7.4%) | 15 (9.3%) | 0.5127 |
| Hepatitis | 15 (9.3%) | 25 (15.4%) | 0.1048 |
| Malignancy | 25 (15.4%) | 21 (13.0%) | 0.5281 |
| Hypertension | 147 (90.7%) | 144 (88.9%) | 0.5485 |
| Acute pancreatitis | 5 (3.1%) | 13 (8.0%) | 0.0593 |
| Other gastrointestinal diseases | 26 (16.1%) | 41 (25.3%) | 0.0287 |
| Basal immunosuppression | |||
| Triple IS | 111 (68.5%) | 123 (75.9%) | 0.0897 |
| Tacrolimus-based IS | 57 (35.2%) | 70 (43.2%) | 0.1682 |
| Cyclosporine-based IS | 77 (47.5%) | 81 (50.0%) | 0.6625 |
| Patients with rATG induction therapy | 3 (1.9%) | 97 (59.9%) | |
| BMI at Month 4–6 after transplant | 26.0±3.7 | 24.2±5.5 | |
| ≥25 | 101 (62.4%) | 57 (35.2%) | |
| Peritransplant Infection (up to 2 mos after transplantation) | 42 (25.9%) | 42 (25.9%) | 1 |
| Severe infection threatening patient or graft survival | 64 (39.51%) | 67 (41.36%) | 0.7357 |
| Mos – months; yrs – years; min – minutes; HLA – human leukocyte antigen; IS – immunosuppression; rATG – rabbit antithymocyte globuline; CMV – Cytomegalovirus; BMI – body mass index. Results are presented as n (%) if data are categorical and for continuous date mean±SD. The p-value refers to a paired t-test for continuous data or McNemar’s test for binary data or Bowker’s Test of Symmetry for more than 2 categories (variable: mismatches). NA: a p-value is not available in case of no discordant pairs (gender and kind of donation were matching variables) or more than 2 categories. | |||